Feb 02, 2024
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 2, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate